Head of Engineering
About the job
- 5–10 years of experience leading and developing software engineering teams.
- Strong coaching, mentoring, and people-management skills.
- A proven track record of building high-performing teams.
- Experience improving execution, delivery, and organizational effectiveness.
- A software engineering background with sufficient technical credibility to work effectively with senior engineers.
- A pragmatic, hands-on approach and a strong sense of ownership.
- A strong ownership mindset and willingness to take responsibility beyond the boundaries of Engineering.
- Curiosity to explore the impact of AI assistance on software development and the willingness to reshape the tech industry, including one's own role.
- Lead, coach, and develop engineers.
- Establish a culture of accountability, trust, and continuous improvement.
- Architect a high-performing team; attract, hire, and retain exceptional talent.
- Establish clear ownership, responsibilities, and improved ways of working.
- Improve planning, prioritization, and execution, and help teams focus on the highest-impact work.
- Apply AI assistance in all steps of the software development lifecycle.
- Increase predictability and transparency of delivery.
- Ensure issues and risks are surfaced early and communicated clearly and openly to relevant stakeholders.
- Create an environment where teams consistently deliver high-quality outcomes.
- Provide coaching, feedback, and career development; support individual growth and leadership development.
- Raise the overall capability of the engineering organization, especially in AI-assisted software development.
- Improve alignment between Engineering, Product, Clinical, Regulatory, and Commercial teams.
- Remove organizational friction and close communication gaps.
- Share global context to ensure engineering stays closely connected to customer and business needs.
- Challenge Product to build the right thing and Engineering to build it the right way.
- Excellent communication and stakeholder-management skills.
- Enjoy and excel at building high-performing teams, developing people, and creating clarity in complex and uncertain environments.
- Care deeply about helping others succeed and building an organization where talented engineers can do their best work.
Head of Engineering (m/f/d)
Company Overview
Mindpeak is a Hamburg-based AI company applying state-of-the-art deep learning to computational pathology, with a clear mission: enabling more effective, personalized cancer treatment.
We work at the intersection of AI, medicine, and drug development-building regulatory-grade solutions that help pharma, biotech, and clinical partners discover, validate, and translate meaningful biomarkers into real-world impact.
Our technology analyzes H&E, IHC, and multiplex tissue data to support drug development, patient stratification, and clinical trials. What makes this work especially rewarding: our AI is already deployed in routine diagnostics in more than 25 countries, meaning the tools we build are used by clinicians and patients every day.
At Mindpeak, we believe that reliable, clinically applicable AI can change how cancer is treated. If you want to work on challenging problems, collaborate across disciplines, and see your work make a real difference in patient care, you’ll feel at home here.
The Role
You will lead and develop our Engineering organization, helping teams operate with greater clarity, accountability, and effectiveness.
Your mission is to ensure our software engineering runs reliably today while building the foundation for future growth. You will help the team deliver predictably, raise quality and ownership, and connect software engineering decisions closely to customer and business needs. You will shape the evolution of our AI-assisted software development lifecycle, driving Engineering to embrace and adopt new ways of building software while ensuring high quality, robustness and reliability, and at substantially increased speed.
You will work closely with Product, Machine Learning, Clinical and QA/Regulatory teams.
What You'll Do
Build and strengthen the engineering team
Lead, coach, and develop engineers
Establish a culture of accountability, trust, and continuous improvement
Architect a high-performing team; attract, hire, and retain exceptional talent
Create structure and clarity
Establish clear ownership, responsibilities, and improved ways of working
Improve planning, prioritization, and execution
Help teams focus on the highest-impact work
Apply AI-assistance in all steps of the Software-Development-Lifecycle
Build a reliable engineering organization
Increase predictability and transparency of delivery
Ensure issues and risks are surfaced early, communicated clearly and openly to relevant stakeholders
Create an environment where teams consistently deliver high-quality outcomes
Develop people and future leaders
Provide coaching, feedback, and career development
Support individual growth and leadership development
Raise the overall capability of the engineering organization, esp. AI-assisted software development
Strengthen cross-functional collaboration
Improve alignment between Engineering, Product, Clinical, Regulatory, and Commercial teams
Remove organizational friction and close communication gaps
Share global context to ensure engineering stays closely connected to customer and business needs
Challenge Product building the RIGHT THING, and Engineering building it the RIGHT WAY
What Success Looks Like After 12 Months
Engineering teams operate with clear ownership and accountability
Delivery is more predictable and transparent
Productivity has increased using AI-assistance while ensuring high quality and full human code accountability
The organization has successfully grown through strong hires
Team engagement and retention remain high
Collaboration across functions is significantly stronger
Engineers spend less time firefighting and more time creating value for customers (<30% unplannable work)
Engineering decisions are strongly connected to customer and business impact.
The team has developed a stronger ownership mindset across functions.
What You Bring
5-10 years of experience leading and developing software engineering teams
Strong coaching, mentoring, and people management skills
A proven track record of building high-performing teams
Experience improving execution, delivery, and organizational effectiveness
Excellent communication and stakeholder management skills
A software engineering background with sufficient technical credibility to work effectively with senior engineers
A pragmatic, hands-on approach and a strong sense of ownership
A strong ownership mindset and willingness to take responsibility beyond the boundaries of Engineering.
Curiosity to explore the impact of AI-assistance on software development and the will to reshape the tech industry, including your own role.
Ideal Candidate
You are an engineering leader who enjoys and excels building high-performing teams, developing people, and creating clarity in complex and uncertain environments.
You care deeply about helping others succeed and building an organization where talented engineers can do their best work.
Why Mindpeak
The opportunity to build AI systems that power both clinical cancer diagnostics and data-driven drug development.
An open, creative work environment with flat hierarchies and quick decision-making.
Be part of an excellent leadership team that invests in continuous development through regular workshops, peer exchange, and coaching
Diverse, engaging projects that help you deepen both your technical and domain expertise.
A centrally located Hamburg office with a beautiful view over the harbor.
Application Details
Please provide:
Your CV
Job references
Your salary expectations and the earliest possible starting date
Note: Direct applicants only. We do not work with recruiting agencies for this position.
About the company
Mindpeak develops an AI-based visual diagnostic platform that helps pathologists analyze breast cancer in digital pathology slides. The platform identifies and quantifies tumor regions and detects breast cancer cells, producing an interpretable report with measurements like tumor size and cell counts that can integrate with existing pathology workflows. It focuses on ease of use and cost effectiveness to bring quantitative microscopic analysis into regular clinical practice, making cancer diagnostic tools accessible beyond specialized labs. Its goal is to improve breast cancer diagnostics by providing accurate, scalable visual analysis that supports faster, more consistent clinical decisions.
Company Size
11-50
Company Stage
Series A
Total Funding
$19.7M
Headquarters
Hamburg, Germany
Founded
2018
Get referred to Mindpeak
See people who can refer or advise you
Simplify's Take
What believers are saying
- Discovery Life Sciences partnered March 24, 2026 to standardize IHC and mIF trials.
- AstraZeneca validation at ESMO 2025 improved HER2 ultralow concordance from 64% to 80%.
- PathGroup rolled Mindpeak into one of the world's largest fully digital pathology networks.
What critics are saying
- Breast HER2 remains RUO in the U.S., blocking routine diagnostic revenue.
- Philips, Paige, and Roche compete for the same digital pathology workflows.
- If Leica and PathGroup prioritize native AI, Mindpeak becomes a feature.
What makes Mindpeak unique
- CE-IVD breast HER2 quantification spans low and ultralow scoring across solid tumors.
- Leica Biosystems began global resale of Mindpeak apps on March 19, 2026.
- Mindpeak's patent filing and mIF workflow integrate image analysis into existing pathology systems.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Flexible Work Hours
- Company Equity
Growth & Insights and Company News
6 month growth
-4%1 year growth
-2%2 year growth
-4%Imagene AI and Mindpeak collaborate to bring ai-powered NSCLC biomarker profiling into digital pathology workflows. Integration brings Imagene AI's Lung Prediction Panel onto Mindpeak's peakDeploy platform, giving laboratories broader access to image-based biomarker profiling HAMBURG, GERMANY, October 19, 2026 / EINPresswire.com / - Hamburg, Germany and Tel Aviv, Israel, October 19, 2026 Imagene AI, a developer of AI-powered pathology assays for precision oncology, and Mindpeak GmbH, a global provider of AI-powered digital pathology solutions, today announced that Imagene AI's non-small cell lung cancer (NSCLC) multi-gene biomarker panel will be integrated into Mindpeak's peakDeploy platform. The companies aim to make H&E-based NSCLC biomarker profiling available within existing laboratory and digital pathology environments. Imagene AI's Lung Prediction Panel is designed to predict genomic alterations, including mutations and fusions in EGFR, KRAS, BRAF, HER2, MET, ALK, ROS1, and RET. The panel is also being expanded to include classifiers for PD-L1 expression and HER2 overexpression. Built on Imagene AI's proprietary foundation models and computational pathology platform, the panel supports biomarker-driven oncology workflows from standard pathology images. Mindpeak has dedicated years of expertise to developing peakDeploy, the infrastructure that embeds tissue AI directly into laboratory workflows, giving pathology teams access to advanced image analysis tools within the systems they already use. Through the collaboration, Imagene AI and Mindpeak will support a more streamlined path for laboratories and pathology networks worldwide to adopt AI-powered biomarker profiling in NSCLC. "This integration with Mindpeak is an important step in making Imagene AI's Lung Prediction Panel available within established digital pathology environments," said Dean Bitan, CEO and Co-founder of Imagene AI. "Together, we are working to bring biomarker intelligence from routine H&E images into digital pathology environments where it can support clinical trial screening, precision diagnostics, and biomarker-driven oncology programs." "We're proud to deepen our collaboration with Imagene, expanding our global deployment infrastructure to bring advanced multi-gene biomarker prediction directly into routine pathology workflows worldwide," said Felix Faber, CEO of Mindpeak GmbH. "The integration of Imagene AI's Lung Prediction Panel into peakDeploy expands the capabilities available through our platform and supports our shared goal of helping laboratories adopt AI-powered pathology solutions in a scalable and practical way." This integration reflects the companies' shared commitment to enabling practical deployment of AI-powered pathology tools in biomarker-driven oncology workflows. Imagene AI and Mindpeak will be available at the upcoming ESMO Congress to discuss how the integration can support broader deployment of AI-powered NSCLC biomarker profiling in digital pathology workflows. Imagene's Lung Prediction Panel is for Research Use Only (RUO) and not for use in diagnostic procedures. About Imagene AI Imagene AI delivers precision Oncology Intelligence through robust multimodal foundation models and proprietary real-world data, accelerating biomarker discovery, patient stratification, response prediction, and companion diagnostic development. From H&E-based molecular profiling to AI-IHC companion diagnostics, Imagene AI develops AI-powered pathology assays that translate biological insight into patient selection and diagnostic strategies. LungOI (R), the first AI-based NSCLC multi-gene biomarker panel to receive a PLA code and CMS payment rate, was developed, validated, and deployed across multiple centers and laboratories globally. Healthcare Industry Today collaborate with leading biopharma organizations to advance biomarker-driven programs from discovery through clinical development and deployment. About Mindpeak GmbH Mindpeak is a leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak's AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images, ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Healthcare Industry Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Mindpeak and Revolune announce commercial co-selling partnership to deliver end-to-end spatial biology solutions. Partnership combines Mindpeak's PhenoScout(TM) AI image analysis with Revolune's multiplex IF kits to streamline the path from tissue staining to spatial discovery HAMBURG, GERMANY, September 21, 2026 /EINPresswire.com/ - Mindpeak, a leader in clinical-grade artificial intelligence for digital pathology, and Revolune, an innovator in accessible multiplex immunofluorescence (mIF) technologies, today announced a commercial co-selling partnership to offer an integrated workflow combining multiplex tissue staining with AI-powered image analysis. Under the agreement, Mindpeak's PhenoScout(TM) AI platform will be offered directly alongside Revolune's multiplex reagent kits, providing researchers with an integrated path from tissue staining to spatial insights. Multiplex immunofluorescence is transforming the way researchers characterize the tumor immune microenvironment, evaluate antibody-drug conjugates (ADCs), and identify translational biomarkers. As spatial biology continues to advance, researchers need workflows that make it easier to generate, interpret, and act on multiplex data with confidence. The Revolune-MindPeak partnership brings these capabilities together in one streamlined workflow: - Flexible Staining: Revolune enables laboratories to move quickly from validated primary antibodies to ready-to-use 4- to 7-plex kits without complex assay development. - Turnkey AI Analysis: PhenoScout AI by Mindpeak automates cell detection, tumor/stroma segmentation, phenotyping, and spatial neighborhood metrics in minutes, eliminating the need for bioinformatics pipelines or manual thresholding. "Multiplex immunofluorescence shouldn't become complicated at the analysis step," said Adrian Arechiga, CCO of Revolune. "Revolune removes the complexity of generating high-quality mIF data. By co-selling Mindpeak's PhenoScout AI, we provide an integrated workflow that takes researchers from antibody staining to quantitative spatial data in minutes, enabling cohort-scale studies without bioinformatics backlogs." "Mindpeak was founded to bring precision, reproducibility, and automation to cellular pathology," said Felix Faber, CEO of Mindpeak. "PhenoScout delivers turnkey spatial analysis out of the box using pre-trained foundation models. Partnering with Revolune creates an ideal synergy, pairing validated staining chemistry directly with fast, reproducible AI analysis." Introductory Launch Promotion To mark the launch, researchers purchasing qualifying Revolune multiplex IF kits will receive promotional PhenoScout AI analysis credits. This introductory offer allows translational teams and CROs to evaluate the complete stain-to-insight workflow on their own tissue samples before transitioning to flexible annual subscription packages. To learn more visit: revolune.com/ai-image-analysis PhenoScout AI is developed by Mindpeak and available through Revolune. For Research Use Only (RUO). About Revolune Revolune is a life science company dedicated to making multiplex immunofluorescence as accessible and practical as routine tissue analysis. Its reagent technologies help laboratories move rapidly from existing primary antibodies to ready-to-use multiplex kits, simplifying spatial biology workflows and enabling researchers to focus on biological questions rather than assay management. About Mindpeak Mindpeak is the leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak's AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images - ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications. For more information, visit www.mindpeak.ai or follow 195 News on LinkedIn. Katja Eisele Mindpeak GmbH +49 40 35676797 email 195 News here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. 195 News do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. You just read: September 21, 2026, 06:30 GMT EIN Presswire's priority is author transparency. 195 News do its best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.
Discovery Life Sciences and Mindpeak partner to bring AI precision to cancer biomarker testing in global clinical trials. Mar 24, 2026, 08:00 ET New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug development HUNTSVILLE, Ala. and HAMBURG, Germany, March 24, 2026 /CNW/ - Inconsistent biomarker interpretation across pathologists remains one of the more stubborn challenges in clinical trial development, contributing to variability in patient stratification and eroding confidence in critical go/no-go decisions. Discovery Life Sciences (Discovery), a provider of biospecimens and biomarker specialty lab services, and Mindpeak, a leading company in AI-powered digital pathology, today announced a partnership designed to address that problem directly, integrating AI-enabled digital image analysis into pathology services for immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) in global clinical trials. The collaboration aims to support biopharma R&D and clinical research by improving biomarker quantification and inter-reader concordance, helping to reduce variability, de-risk biomarker-driven trials and strengthen confidence in critical development decisions. The partnership couples Mindpeak's AI platform with Discovery's tissue biomarker services to analyze IHC and mIF slides. Mindpeak's technology acts as a safeguarding tool for biopharma, reducing risks in biomarker development by improving consistency in interpretation across pathologists. It includes AI-enabled pathology workflows, pathologist training via Mindpeak's peakAcademy, and AI-guided microdissection algorithms to isolate specific tissue regions with high accuracy. Discovery brings significant clinical infrastructure to the alliance. Its Biomarker Academy, a peer-to-peer pathologist training program established in 2008, has trained more than 6,000 pathologists in biomarker interpretation and scoring over the past 15 years. Discovery has supported more than 2,000 clinical trial programs, with 350 currently active, and has completed over 35 IVDR-compliant studies across 16 EU countries involving 25 biomarkers in the past four years. This partnership extends Discovery's AI advancements, building on existing H&E-focused AI solutions for biospecimen analysis, including automated quality control, tumor quantification, and detailed tumor microenvironment characterization across various therapeutic areas. "As AI use in pathology increases for clinical research, this partnership with Mindpeak allows integration of modeling tools that can enable improved accuracy in biomarker analysis," said Greg Herrema, CEO of Discovery Life Sciences. "Combining these AI capabilities with our clinical trials expertise will help assist in advancing the development of biomarker-focused therapies." The Mindpeak and Discovery alliance aims to streamline trial processes and enhance data reproducibility in regulated settings, supporting more confident decisions in patient stratification and therapeutic development. "This collaboration with Discovery Life Sciences provides access to our AI platform, training and microdissection tools, supporting researchers in IHC and mIF applications and helping to drive greater consistency and confidence in biomarker assessment," said Felix Faber, Founder and CEO of Mindpeak. Additional details on the partnership and use cases will be presented at the AACR Annual Meeting 2026. Attendees can join a flash talk at the Discovery Life Sciences exhibit from April 17-22 at the San Diego Convention Center in San Diego, California. Contact [email protected] for more information. About Discovery Life Sciences Discovery Life Sciences is a global leader in biospecimens and specialty lab services, enabling the discovery and development of therapeutics and diagnostics that improve patient outcomes. Our extensive portfolio of biospecimens, cellular starting materials, and preclinical ADME-tox solutions accelerates research with reliable, high-quality products and expertise. Through our comprehensive suite of specialty lab services in genomics, proteomics, cell biology, and molecular pathology, we deliver critical data and insights for biomarker discovery and both retrospective and prospective clinical trials. With a vision to be the most trusted partner in life science research and clinical development, Discovery Life Sciences is committed to advancing life sciences and transforming lives. Visit www.dls.com and follow us on LinkedIn for more information. About Mindpeak Mindpeak is the leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak's AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images - ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications. Discovery Life Sciences Media Todd Poley Chief Marketing Officer +1 256 505 1578 [email protected] Mindpeak Media Tanya von Ahlefeldt MD Health - on behalf of Mindpeak +44 (0)7590 754906 [email protected] SOURCE Discovery Life Sciences
Mindpeak, an AI-driven pathology startup, raised $15.3 million in a Series A round led by ZEISS Ventures and InnoVentureFund in 2024. The funding will accelerate development and deployment of the company's AI diagnostic tools for cancer pathology. Founded in 2018, Mindpeak's algorithms have supported over 30,000 patient diagnoses across US and European healthcare markets. The technology uses automated histological analyses to help pathologists make faster, more precise clinical decisions. CEO Felix Faber stated the capital would expedite product rollouts and expand capabilities. The company has established strategic partnerships with major players including Roche. Mindpeak operates in the rapidly growing digital pathology market, driven by technological innovation and increasing demand for advanced diagnostic services in an ageing population.
PathGroup chooses mindpeak to power its digital pathology transformation. PathGroup and Mindpeak: Collaboration accelerates AI adoption across one of the world's largest fully digital laboratory networks HAMBURG, GERMANY, November 11, 2025 /EINPresswire.com/ - Mindpeak, a global pioneer in AI-powered pathology solutions, today announced a strategic collaboration with PathGroup, a premier provider of anatomic, clinical, molecular and digital pathology services. The collaboration marks a significant milestone in the evolution of AI-driven pathology, uniting Mindpeak's proprietary image analysis technology with PathGroup's extensive, pathologist-led diagnostic network. By combining deep pathology expertise with advanced AI, the collaboration will accelerate the adoption of scalable, interoperable solutions across large diagnostic networks and research environments. PathGroup operates one of the largest fully digitised pathology networks in the world and is widely recognised as a pioneer in diagnostic innovation. With its advanced digital infrastructure, subspecialist pathologists and streamlined workflows, PathGroup represents an ideal environment to scale AI adoption and set new standards for diagnostic excellence. "As our practice has continued to adopt and integrate industry leading-technology solutions, it makes perfect sense that we would be partnering with Mindpeak for at-scale use of best-in-class AI algorithms, to the benefit of the patients we serve," said Derek C. Welch, MD, FCAP, President and Chief Medical Officer at PathGroup. "This is especially true for cancer patients. The team at Mindpeak share the notion that computational pathology and artificial intelligence are here now and have the power to enhance patient lives today. The tools Mindpeak brings to the market certainly support this notion and we are excited to be partners at this pivotal time in global pathology service transformation. It is truly exciting." Felix Faber, Founder and CEO of Mindpeak, commented: "We're delighted to partner with PathGroup - a leader whose values and expertise align closely with our mission to make AI an everyday tool in pathology. Together, we're pioneering innovation in digital diagnostics and helping laboratories and clinicians deliver faster, more consistent and equitable insights for patients. This collaboration represents a major step forward in bringing the benefits of AI into routine diagnostic practice." Erik Piorkowski, Mindpeak's Head of Diagnostic Sales, Americas, added: "The collaboration will begin with the deployment of Mindpeak's Breast Suite and PD-L1 AI solutions, supporting macro-dissection workflows and expanding decision-support capabilities across PathGroup's large-scale operations. This marks an exciting step forward in accelerating the integration of AI-powered precision into diagnostic practice." By leveraging PathGroup's vast diagnostic network and expert pathologist community, the rollout will generate robust clinical evidence and drive real-world adoption across multiple laboratory settings. This will help lay the foundation for broader digital transformation across pathology services. As Imad B. Nijim, Senior Vice President and Chief Information Officer, PathGroup, noted: "At PathGroup, we are committed to a digital transformation that harnesses cutting-edge technology to advance diagnostic precision and patient care. Our collaboration with Mindpeak represents a significant step toward integrating AI into our pathology workflows. I am excited about this partnership as it reflects a shared vision for a future where artificial intelligence is seamlessly embedded in healthcare, transforming how we detect, diagnose, understand and treat diseases." Together, Mindpeak and PathGroup are laying the foundation for the next wave of AI-powered decision support in pathology. PathGroup's more than 240 sub-specialty expert pathologists will utilise Mindpeak's solutions as they collaborate seamlessly to drive unsurpassed diagnostic precision for patient and physicians. This rollout will also generate robust clinical evidence to accelerate adoption across diverse laboratory settings. Key benefits of the collaboration include: | Accelerated AI adoption - enabling faster implementation of digital pathology in high-throughput diagnostic environments. | Enhanced diagnostic consistency - reducing inter-observer variability and supporting confident clinical decisions. | Scalable insights - integrating AI seamlessly across multi-site networks and research programmes. | Future-ready innovation - advancing biomarker discovery, predictive analytics and personalised medicine. This collaboration reflects Mindpeak's continued growth in the US, following the opening of its office in Boston, Massachusetts earlier this year and reinforces its ambition to shape the future of pathology through AI - from translational research to clinical diagnostics - around the world. About mindpeak. Mindpeak is the leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak's AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images - ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications. About PathGroup. Founded in 1965, PathGroup is a premier provider of anatomic, clinical, molecular and digital pathology services in the United States. As a physician-led practice, PathGroup works seamlessly with customers to provide superior diagnostic services - a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry-standard technology, including an industry-leading deployment of digital pathology across its organization, to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. PathGroup is more than a laboratory - it is a trusted partner in health, driven by a mission to improve lives through diagnostic excellence and innovation. Media contacts. Tanya von Ahlefeldt MD Health - on behalf of Mindpeak [email protected] +44 (0)7590 754906 Brent Sower Vice President of Commercial Strategy - PathGroup [email protected] 615-234-3908